Francesco M. Marincola, MD, FACS
Chief Research Officer
Sidra Medical and Research Center
Dr. Francesco M. Marincola, MD, FACS, is the inaugural Chief Research Officer of Sidra Medical and
Research Center, a unique hospital and research center in Doha, Qatar. Dr. Marincola will lead the
development of Sidra’s research capabilities to create a center of excellence for research focusing on
medical conditions, epidemiology and issues that primarily afflict the people of the Arab world, including
diabetes, cancer and fetal-maternal health.
Dr. Marincola joins Sidra from the U.S. National Institutes of Health (NIH), where he held the positions of
Chief of the Infectious Disease and Immunogenetics Section (IDIS) and Tenured Senior Investigator. He
was also Director or the Immunogenetics Program, Department of Transfusion Medicine, Director of the
Federation of Clinical Immunology Societies (FOCIS) Center for Excellence and Co-Director of the TransNIH Center for Human Immunology. He is President of the Society for the Immunotherapy of Cancer and
President of the International Society for Translational Medicine.
Dr. Marincola is actively involved with a number of leading academic journals. In 2003, he founded the
Journal of Translational Medicine and is currently its Editor-in-Chief; he is Co-Editor-in-Chief of Clinical
and Translational Medicine and Genetic Medicine; U.S. Senior Editor of Immunotherapy; Associate Editor
for The Journal of Immunotherapy, Tumori, and Clinical Cancer Research. He is also Adjunct Professor at
Peking Union Medical College, Beijing, China; First Military Medical University, Tonghe, Guangzhou,
China; Shenzhen Institute of Xiangxya Biomedicine, Shenzhen, China and Universidad del Rosario,
Bogota, Colombia. In addition, Dr. Marincola served and serves on several advisory boards, currently
including the National Cancer Institute (NCI), the Cancer Immunology Trial Network and the Pharma
Foundation, and is on the steering committee for the worldwide cancer immunotherapy immunoscore
initiative.
Dr. Marincola received his MD summa cum laude from the University of Milan and his surgery training
from Stanford University. He is the author of more than 500 peer-reviewed research articles and his work
has been cited more than 16,000, times with an average of 1,200 citations per year and an H index of 63.
He has been invited to speak at over 300 national and international meetings. Dr. Marincola is the second
most cited scientist in the field of melanoma during the last ten years, with 55 papers cited 3,704 times to
date. His research interest is primarily translational and focuses on the development of strategies for the
dynamic study of patients’ response to therapies. His approach has deepened understanding of the
mechanisms leading to rejection of tumors, allograft, graft versus host disease and leading to the
development of autoimmunity.
1